Carolyn T. Thorpe, Richa Gairola. "Real-world patterns of dose reduction and early discontinuation of abemaciclib for early-stage, hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer in insured United States adults.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.e12718